NEOS S&P 500 High Income ETF vs Tilray Brands Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $52.93, while Tilray Brands Inc trades at $4.25 (market cap $524.07M). The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| SPYI | TLRY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $54.07 | $21.00 |
52-Week Low | $47.98 | $4.23 |
Market Cap | — | $524.07M |
Enterprise Value | — | $621.22M |
Signals from Pluang's Aura AI — not financial advice
SPYI (NEOS S&P 500 High Income ETF) trades at $53.01, down 0.11% with a bearish technical signal. The fund has grown to over $10 billion in assets under management and delivers consistent monthly distributions through its covered call strategy. Recent performance shows 8% year-to-date and 19% one-year returns, though trailing the broader S&P 500. The ETF's two-leg options strategy enables robust income generation while retaining partial upside exposure.
SPYI offers investors high-yield income with downside protection, making it attractive for retirement portfolios. However, the fund's 0.68% expense ratio and potential return of capital distributions require careful consideration. Market volatility benefits the options strategy, but sustained bull markets may limit upside participation compared to traditional index funds.
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Trailing returns across standard periods
Latest headlines on both assets
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →